StockData
Sigyn Therapeutics, Inc. logo

Sigyn Therapeutics, Inc. (SIGY) shareholders

SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2025, quý kết thúc ngày Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 0/30
$0.03+0.00 (0.00%)

Close on Oct 19, 2026Market cap $48.16KP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
3.3%
0M of 2M shares
Institutional holders
1
1 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Brio Capital Master Fund Ltd.
Joint filing with Brio Capital Management LLC (9.99%)
160,5379.99%13G (passive) amendmentDec 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SIGYValueChange% of portfolio
Howard Capital Management Group, LLC53,0003.30%$1.35KNew0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202610M3.3%1 / 00 / 00M0M

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Joseph Segelman
Chief Executive Officer, Director, 10% owner
Jun 23, 2017Buy+8,500$0.08$68025,021,000
Joseph Segelman
Chief Executive Officer, Director, 10% owner
Jun 23, 2017Buy+8,500$0.18$1.53K25,021,000
Joseph Segelman
CEO, Director, 10% owner
Mar 29, 2017Buy+2,500$0.12$30025,012,500
Joseph Segelman
CEO, Director, 10% owner
Dec 19, 2016Buy+5,000$0.10$50025,010,000
Joseph Segelman
CEO, Director, 10% owner
Dec 14, 2016Buy+5,000$0.10$50025,005,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
–
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Sigyn Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 300 shares on Aug 26, 2026 over the last 90 days.

See a number that looks wrong?